Literature DB >> 27393490

Binary toxin and its clinical importance in Clostridium difficile infection, Belgium.

T Pilate1, J Verhaegen2, M Van Ranst2, V Saegeman2.   

Abstract

Binary toxin-producing Clostridium difficile strains such as ribotypes 027 and 078 have been associated with increased Clostridium difficile infection (CDI) severity. Our objective was to investigate the association between presence of the binary toxin gene and CDI severity and recurrence. We performed a laboratory-based retrospective study including patients between January 2013 and March 2015 whose fecal samples were analyzed by polymerase chain reaction (PCR) for the presence of the genes for toxin B and binary toxin and a deletion in the tcdC gene, specific for ribotype 027. Clinical and epidemiological characteristics were compared between 33 binary toxin-positive CDI patients and 33 binary toxin-negative CDI patients. Subsequently, the characteristics of 66 CDI patients were compared to those of 66 diarrhea patients who were carriers of non-toxigenic C. difficile strains. Fifty-nine of 1034 (5.7 %) fecal samples analyzed by PCR were binary toxin-positive, belonging to 33 different patients. No samples were positive for ribotype 027. Binary toxin-positive CDI patients did not differ from binary toxin-negative CDI patients in terms of disease recurrence, morbidity, or mortality, except for a higher peripheral leukocytosis in the binary toxin-positive group (16.30 × 109/L vs. 11.65 × 109/L; p = 0.02). The second part of our study showed that CDI patients had more severe disease, but not a higher 30-day mortality rate than diarrhea patients with a non-toxicogenic C. difficile strain. In our setting with a low prevalence of ribotype 027, the presence of the binary toxin gene is not associated with poor outcome.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27393490     DOI: 10.1007/s10096-016-2719-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  24 in total

Review 1.  Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

Authors:  Claudia Thomas; Mark Stevenson; Thomas V Riley
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

Review 2.  The role of toxin A and toxin B in the virulence of Clostridium difficile.

Authors:  Glen P Carter; Julian I Rood; Dena Lyras
Journal:  Trends Microbiol       Date:  2011-12-07       Impact factor: 17.079

3.  Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis.

Authors:  S L Peach; S P Borriello; H Gaya; F E Barclay; A R Welch
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

4.  Host and pathogen factors for Clostridium difficile infection and colonization.

Authors:  Vivian G Loo; Anne-Marie Bourgault; Louise Poirier; François Lamothe; Sophie Michaud; Nathalie Turgeon; Baldwin Toye; Axelle Beaudoin; Eric H Frost; Rodica Gilca; Paul Brassard; Nandini Dendukuri; Claire Béliveau; Matthew Oughton; Ivan Brukner; Andre Dascal
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

5.  Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile.

Authors:  Simon D Goldenberg; Gary L French
Journal:  J Infect       Date:  2011-03-21       Impact factor: 6.072

6.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.

Authors:  E J Kuijper; F Barbut; J S Brazier; N Kleinkauf; T Eckmanns; M L Lambert; D Drudy; F Fitzpatrick; C Wiuff; D J Brown; J E Coia; H Pituch; P Reichert; J Even; J Mossong; A F Widmer; K E Olsen; F Allerberger; D W Notermans; M Delmée; B Coignard; M Wilcox; B Patel; R Frei; E Nagy; E Bouza; M Marin; T Akerlund; A Virolainen-Julkunen; O Lyytikäinen; S Kotila; A Ingebretsen; B Smyth; P Rooney; I R Poxton; D L Monnet
Journal:  Euro Surveill       Date:  2008-07-31

7.  Clostridium difficile in patients with cystic fibrosis.

Authors:  C J Welkon; S S Long; C M Thompson; P H Gilligan
Journal:  Am J Dis Child       Date:  1985-08

8.  Binary toxin and death after Clostridium difficile infection.

Authors:  Sabrina Bacci; Kåre Mølbak; Marianne K Kjeldsen; Katharina E P Olsen
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

Review 9.  Clostridium difficile binary toxin CDT: mechanism, epidemiology, and potential clinical importance.

Authors:  Dale N Gerding; Stuart Johnson; Maja Rupnik; Klaus Aktories
Journal:  Gut Microbes       Date:  2013-10-31

10.  Helicobacter pylori and Clostridium difficile in cystic fibrosis patients.

Authors:  Jacob Yahav; Zmira Samra; Hannah Blau; Gabriel Dinari; Gabriel Chodick; Haim Shmuely
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

View more
  3 in total

1.  Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.

Authors:  Marie Pichenot; Rozenn Héquette-Ruz; Remi Le Guern; Bruno Grandbastien; Clément Charlet; Frédéric Wallet; Sophie Schiettecatte; Fanny Loeuillet; Benoit Guery; Tatiana Galperine
Journal:  Infection       Date:  2017-01-24       Impact factor: 3.553

Review 2.  An Update on Clostridioides difficile Binary Toxin.

Authors:  Adrián Martínez-Meléndez; Flora Cruz-López; Rayo Morfin-Otero; Héctor J Maldonado-Garza; Elvira Garza-González
Journal:  Toxins (Basel)       Date:  2022-04-27       Impact factor: 5.075

3.  Structure of the cell-binding component of the Clostridium difficile binary toxin reveals a di-heptamer macromolecular assembly.

Authors:  Xingjian Xu; Raquel Godoy-Ruiz; Kaylin A Adipietro; Christopher Peralta; Danya Ben-Hail; Kristen M Varney; Mary E Cook; Braden M Roth; Paul T Wilder; Thomas Cleveland; Alexander Grishaev; Heather M Neu; Sarah L J Michel; Wenbo Yu; Dorothy Beckett; Richard R Rustandi; Catherine Lancaster; John W Loughney; Adam Kristopeit; Sianny Christanti; Jessica W Olson; Alexander D MacKerell; Amedee des Georges; Edwin Pozharski; David J Weber
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-02       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.